BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26908323)

  • 1. A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer.
    Annaházi A; Ábrahám S; Farkas K; Rosztóczy A; Inczefi O; Földesi I; Szűcs M; Rutka M; Theodorou V; Eutamene H; Bueno L; Lázár G; Wittmann T; Molnár T; Róka R
    Br J Cancer; 2016 Mar; 114(7):787-92. PubMed ID: 26908323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening.
    Otero-Estévez O; De Chiara L; Rodríguez-Girondo M; Rodríguez-Berrocal FJ; Cubiella J; Castro I; Hernández V; Martínez-Zorzano VS
    Sci Rep; 2015 Aug; 5():13030. PubMed ID: 26264519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
    Haug U; Hundt S; Brenner H
    Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
    Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
    Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
    Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
    Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of faecal
    Wong SH; Kwong TNY; Chow TC; Luk AKC; Dai RZW; Nakatsu G; Lam TYT; Zhang L; Wu JCY; Chan FKL; Ng SSM; Wong MCS; Ng SC; Wu WKK; Yu J; Sung JJY
    Gut; 2017 Aug; 66(8):1441-1448. PubMed ID: 27797940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study.
    de Meij TG; Larbi IB; van der Schee MP; Lentferink YE; Paff T; Terhaar Sive Droste JS; Mulder CJ; van Bodegraven AA; de Boer NK
    Int J Cancer; 2014 Mar; 134(5):1132-8. PubMed ID: 23959518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test.
    Otero-Estévez O; De Chiara L; Rodríguez-Berrocal FJ; Páez de la Cadena M; Cubiella J; Castro I; Gonzalez-Mao C; Hernandez V; Martínez-Zorzano VS
    Br J Cancer; 2015 Jan; 112(2):375-81. PubMed ID: 25461801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
    Shastri YM; Stein JM
    Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.
    De Chiara L; Rodríguez-Piñeiro AM; Rodríguez-Berrocal FJ; Cordero OJ; Martínez-Ares D; Páez de la Cadena M
    BMC Cancer; 2010 Jun; 10():333. PubMed ID: 20584285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence.
    Gimeno-García AZ; Santana-Rodríguez A; Jiménez A; Parra-Blanco A; Nicolás-Pérez D; Paz-Cabrera C; Díaz-González F; Medina C; Díaz-Flores L; Quintero E
    Eur J Cancer; 2006 Dec; 42(18):3246-52. PubMed ID: 16973348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
    Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
    Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
    Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
    Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
    Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer.
    Kanaan Z; Roberts H; Eichenberger MR; Billeter A; Ocheretner G; Pan J; Rai SN; Jorden J; Williford A; Galandiuk S
    Ann Surg; 2013 Sep; 258(3):400-8. PubMed ID: 24022433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms.
    Godber IM; Todd LM; Fraser CG; MacDonald LR; Younes HB
    Clin Chem Lab Med; 2016 Apr; 54(4):595-602. PubMed ID: 26457785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.
    Tutton MG; George ML; Eccles SA; Burton S; Swift RI; Abulafi AM
    Int J Cancer; 2003 Nov; 107(4):541-50. PubMed ID: 14520690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.